Table 2. Cost (in CNY) per instance of different outcomes, pre-vaccination, and post-vaccination.
| Group | Pre-vaccination | Post-vaccination | ||||||||||
| AECOPD | Pneumonia | AECOPD& pneumonia | AECOPD& Hospitalization | Pneumonia& hospitalization | AECOPD& pneumonia& hospitalization | AECOPD | AECOPD& pneumonia | AECOPD& hospitalization | Pneumonia& hospitalization | AECOPD& pneumonia& hospitalization | ||
| Note: “–” means no outcome was reported. Abbreviation: TIV=trivalent influenza vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine; AECOPD=acute exacerbation of chronic obstructive pulmonary disease. * P=0.01; † P=0.004; § P<0.001; ¶ P=0.04. | ||||||||||||
| TIV group | 701.1 | – | 1,069.1 | 13,146.5 | 5,433.3 | 9,549.7 | – | 1,566.7 | 10,903.1 | 18,617.2 | 11,633.2 | |
| PPSV23 group | 1,103.6 | – | 1,363.9 | 6,667.4* | – | 8,449.1 | 722.2 | 2,500.0 | 11,147.6* | – | 10,102.1 | |
| TIV&PPSV23 group | 649.3 | 1,231.3 | 805.5 | 8,810.2 | 9,140.6 | 8,134.6 | 1,057.4 | 1,343.3 | 11,877.6 | 14,276.4 | 12,777.0 | |
| Unvaccinated group | 550.5 | 2,000.0 | 1,276.9 | 12,509.2† | 7,510.0 | 10,591.5§ | 716.0 | 1,000.0 | 15,098.8† | – | 13,962.0§ | |
| Total | 751.4 | 1,423.5 | 986.0 | 9,852.1 | 7,908.8 | 8,814.9¶ | 922.7 | 1,550.7 | 12,337.4 | 16,446.8 | 12,349.5¶ | |